KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Debt (2017 - 2023)

Bionano Genomics (BNGO) has disclosed Total Debt for 7 consecutive years, with $10.0 million as the latest value for Q3 2023.

  • Quarterly Total Debt rose 7.49% to $10.0 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Sep 2023, up 7.49% year-over-year, with the annual reading at $9.4 million for FY2022, N/A changed from the prior year.
  • Total Debt hit $10.0 million in Q3 2023 for Bionano Genomics, roughly flat from $10.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $20.1 million in Q4 2019 to a low of $9.2 million in Q2 2022.
  • Historically, Total Debt has averaged $14.3 million across 5 years, with a median of $15.7 million in 2020.
  • Biggest five-year swings in Total Debt: soared 122.44% in 2019 and later dropped 19.09% in 2020.
  • Year by year, Total Debt stood at $20.1 million in 2019, then dropped by 18.72% to $16.3 million in 2020, then dropped by 8.94% to $14.9 million in 2021, then plummeted by 36.89% to $9.4 million in 2022, then rose by 6.59% to $10.0 million in 2023.
  • Business Quant data shows Total Debt for BNGO at $10.0 million in Q3 2023, $10.0 million in Q2 2023, and $9.5 million in Q1 2023.